Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04354870 · ClinicalTrials.gov registry record · Phase 2
COVID-19 PrEP HCW HCQ Study
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT04354870 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 130 participants.
The verdict
NCT04354870, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 350 participants will be assigned to the group that takes HCQ or the group that opts to not take the study medication. Participants will be NYULH HCW at high risk for occupational exposure to SARS-CoV-2. Study timepoints will include screening/enrollment, 30 day, 60 day, and 90 day visits. Questionnaires, and DBS will be collected in all timepoints.
Interventions
- DRUG Hydroxychloroquine (HCQ)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2020-04-03 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04354870
The ClinicalTrials.gov registry entry for NCT04354870 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxychloroquine (HCQ) is the first listed.
NCT04354870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04354870 about?
NCT04354870 is a clinical study titled "COVID-19 PrEP HCW HCQ Study". Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 350 participants will be assigned to the group that takes HCQ or the group that opts to not take the study medication. Participants w...
What is the current status of trial NCT04354870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2020-04-03. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT04354870?
The interventions under investigation include: Hydroxychloroquine (HCQ) (DRUG).
Who is sponsoring clinical trial NCT04354870?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.